Your browser doesn't support javascript.
In adults hospitalized with COVID-19, adding baricitinib vs. dexamethasone to remdesivir did not differ for MV-free survival.
Tran, Alexandre; Rochwerg, Bram.
  • Tran A; University of Ottawa, Ottawa, Ontario, Canada (A.T.).
  • Rochwerg B; McMaster University, Hamilton, Ontario, Canada (B.R.).
Ann Intern Med ; 175(10): JC115, 2022 10.
Article in English | MEDLINE | ID: covidwho-2110760
ABSTRACT
SOURCE CITATION Wolfe CR, Tomashek KM, Patterson TF, et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4) a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022;10888-99. 35617986.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Adult / Humans Language: English Journal: Ann Intern Med Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Adult / Humans Language: English Journal: Ann Intern Med Year: 2022 Document Type: Article